Recent advancements of antiangiogenic combination therapies in ovarian cancer

Ovarian cancer is the most lethal gynecological malignancy [1], responsible for nearly 5% of all cancer deaths despite the fact that it only accounts for 2.5% of all malignancies in women [2]. The disease presents at late stages in most cases and ultimately proves fatal to over 75% of those diagnosed with advanced tumors [3], with 70-80% of patients developing a relapse after upfront surgical debulking and chemotherapy [4]. The critical unmet need for more effective therapy has therefore spurred on the development of a more tailored and precision-based medicine.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research